Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more
Gilead Sciences Inc - Asset Resilience Ratio
Gilead Sciences Inc (GILD) has an Asset Resilience Ratio of 17.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Gilead Sciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gilead Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.61 Billion | 17.97% |
| Total Liquid Assets | $10.61 Billion | 17.97% |
Asset Resilience Insights
- Good Liquidity Position: Gilead Sciences Inc maintains a healthy 17.97% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Gilead Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Gilead Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Gilead Sciences Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Gilead Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.67% | $1.58 Billion | $58.99 Billion | +0.78pp |
| 2023-12-31 | 1.90% | $1.18 Billion | $62.12 Billion | +0.36pp |
| 2022-12-31 | 1.54% | $973.00 Million | $63.17 Billion | -0.20pp |
| 2021-12-31 | 1.74% | $1.18 Billion | $67.95 Billion | -0.32pp |
| 2020-12-31 | 2.06% | $1.41 Billion | $68.41 Billion | -18.58pp |
| 2019-12-31 | 20.64% | $12.72 Billion | $61.63 Billion | +1.56pp |
| 2018-12-31 | 19.08% | $12.15 Billion | $63.67 Billion | -6.42pp |
| 2017-12-31 | 25.50% | $17.92 Billion | $70.28 Billion | +19.07pp |
| 2016-12-31 | 6.43% | $3.67 Billion | $56.98 Billion | +3.05pp |
| 2015-12-31 | 3.39% | $1.76 Billion | $51.84 Billion | +3.10pp |
| 2014-12-31 | 0.29% | $101.00 Million | $34.66 Billion | +0.21pp |
| 2013-12-31 | 0.08% | $19.00 Million | $22.58 Billion | -0.19pp |
| 2012-12-31 | 0.28% | $58.56 Million | $21.24 Billion | +0.18pp |
| 2011-12-31 | 0.10% | $16.49 Million | $17.30 Billion | -10.18pp |
| 2010-12-31 | 10.27% | $1.19 Billion | $11.59 Billion | +6.31pp |
| 2009-12-31 | 3.96% | $384.02 Million | $9.70 Billion | -0.81pp |
| 2008-12-31 | 4.77% | $330.76 Million | $6.94 Billion | +1.27pp |
| 2007-12-31 | 3.49% | $203.89 Million | $5.83 Billion | +0.54pp |
| 2006-12-31 | 2.96% | $120.84 Million | $4.09 Billion | -39.61pp |
| 2005-12-31 | 42.56% | $1.60 Billion | $3.77 Billion | -2.57pp |
| 2004-12-31 | 45.14% | $973.13 Million | $2.16 Billion | +12.19pp |
| 2003-12-31 | 32.95% | $512.28 Million | $1.55 Billion | +7.69pp |
| 2002-12-31 | 25.26% | $325.44 Million | $1.29 Billion | -32.53pp |
| 2001-12-31 | 57.80% | $459.36 Million | $794.79 Million | +11.26pp |
| 2000-12-31 | 46.54% | $315.59 Million | $678.10 Million | -10.09pp |
| 1999-12-31 | 56.63% | $247.38 Million | $436.81 Million | -- |